KTD-092, a DYRK1A inhibitor, exhibits an IC50 of 22 nM against human DYRK1A. It is applicable in research related to Down syndrome (DS), Alzheimers disease (AD), autism spectrum disorder (ASD), diabetes, and other neurodegenerative diseases.
Target:
DYRK
* VAT and and shipping costs not included. Errors and price changes excepted
